-
公开(公告)号：US08232071B2
公开(公告)日：2012-07-31
申请号：US12817105
申请日：2010-06-16
申请人： Irving L. Weissman , Naoki Hosen
发明人： Irving L. Weissman , Naoki Hosen
CPC分类号： G01N33/57426 , C12Q1/34 , G01N33/5011
摘要： Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.
摘要翻译： 确定急性骨髓性白血病干细胞（AMLSC）。 可以从患者样品前瞻性分离或鉴定细胞，并且在癌症干细胞自我更新和分化以及癌症诊断的功能测定中显示具有癌干细胞的独特性质。
-
公开(公告)号：US20100255575A1
公开(公告)日：2010-10-07
申请号：US12817105
申请日：2010-06-16
申请人： Irving L. Weissman , Naoki Hosen
发明人： Irving L. Weissman , Naoki Hosen
IPC分类号： C12N5/09
CPC分类号： G01N33/57426 , C12Q1/34 , G01N33/5011
摘要： Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.
摘要翻译： 确定急性骨髓性白血病干细胞（AMLSC）。 可以从患者样品前瞻性分离或鉴定细胞，并且在癌症干细胞自我更新和分化以及癌症诊断的功能测定中显示具有癌干细胞的独特性质。
-
公开(公告)号：US07767410B2
公开(公告)日：2010-08-03
申请号：US11999809
申请日：2007-12-07
申请人： Irving L. Weissman , Naoki Hosen
发明人： Irving L. Weissman , Naoki Hosen
CPC分类号： G01N33/57426 , C12Q1/34 , G01N33/5011
摘要： Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.
摘要翻译： 确定急性骨髓性白血病干细胞（AMLSC）。 可以从患者样品前瞻性分离或鉴定细胞，并且在癌症干细胞自我更新和分化以及癌症诊断的功能测定中显示具有癌干细胞的独特性质。
-
公开(公告)号：US20080187950A1
公开(公告)日：2008-08-07
申请号：US11999809
申请日：2007-12-07
申请人： Irving L. Weissman , Naoki Hosen
发明人： Irving L. Weissman , Naoki Hosen
CPC分类号： G01N33/57426 , C12Q1/34 , G01N33/5011
摘要： Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.
摘要翻译： 确定急性骨髓性白血病干细胞（AMLSC）。 可以从患者样品前瞻性分离或鉴定细胞，并且在癌症干细胞自我更新和分化以及癌症诊断的功能测定中显示具有癌干细胞的独特性质。
-
5.发明申请公开(公告)号：US20120045446A1
公开(公告)日：2012-02-23
申请号：US13263206
申请日：2010-04-09
申请人： Naoki Hosen , Haruo Sugiyama
发明人： Naoki Hosen , Haruo Sugiyama
IPC分类号： A61K39/395 , G01N33/577 , G01N33/566 , C07K16/28 , A61P35/00
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2803 , C07K2317/73 , C07K2317/734 , G01N33/5011 , G01N2333/70503 , G01N2500/04
摘要： The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes: (1) a process of sorting a substance that binds specifically to human CD48; and (2) a process of sorting a substance having cellular cytotoxicity.
摘要翻译： 本发明提供了治疗剂，用于发生血浆细胞的肿瘤增生的疾病，其特征在于含有抗人CD48单克隆抗体并且对表达人CD48的细胞具有细胞毒性; 和单克隆抗体。 此外，本发明提供了筛选发生血浆细胞肿瘤增生的疾病的治疗剂的活性成分的方法，所述方法包括以下方法：（1）对与人特异性结合的物质进行分选的方法 CD48; 和（2）分选具有细胞毒性的物质的方法。
-
6.发明授权Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies 有权通过施用抗CD48抗体杀死骨髓瘤干和前体细胞的方法公开(公告)号：US09097717B2
公开(公告)日：2015-08-04
申请号：US13263206
申请日：2010-04-09
申请人： Naoki Hosen , Haruo Sugiyama
发明人： Naoki Hosen , Haruo Sugiyama
IPC分类号： A61K39/395 , G01N33/574 , C07K16/28 , G01N33/50 , A61K39/00
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2803 , C07K2317/73 , C07K2317/734 , G01N33/5011 , G01N2333/70503 , G01N2500/04
摘要： The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes: (1) a process of sorting a substance that binds specifically to human CD48; and (2) a process of sorting a substance having cellular cytotoxicity.
摘要翻译： 本发明提供了治疗剂，用于发生血浆细胞的肿瘤增生的疾病，其特征在于含有抗人CD48单克隆抗体并且对表达人CD48的细胞具有细胞毒性; 和单克隆抗体。 此外，本发明提供了筛选发生血浆细胞肿瘤增生的疾病的治疗剂的活性成分的方法，所述方法包括以下方法：（1）对与人特异性结合的物质进行分选的方法 CD48; 和（2）分选具有细胞毒性的物质的方法。
-
7.发明申请Methods for Separating Hepatic, Endothelial, or Hematopoietic Progenitor Cells From Cell Populations 审中-公开从细胞群体分离肝，内皮细胞或造血祖细胞的方法公开(公告)号：US20080003637A1
公开(公告)日：2008-01-03
申请号：US10594605
申请日：2005-03-28
申请人： Haruo Sugiyama , Naoki Hosen , N.D. Hastie
发明人： Haruo Sugiyama , Naoki Hosen , N.D. Hastie
IPC分类号： C12Q1/06
CPC分类号： G01N33/56966 , C12N5/0647 , C12N5/0672
摘要： The present inventors succeeded in FACS-sorting viable WT1-expressing cells, and also discovered that WT1 expression in mouse fetal liver cells serves as a common molecular marker of hepatic, endothelial, and hematopoietic progenitor cells. Based on the present invention, hepatic, endothelial, and hematopoietic progenitor cells can be separated or detected using the WT1 gene expression level as an indicator.
摘要翻译： 本发明人成功地将FACS分选出可行的WT1表达细胞，并且还发现小鼠胎儿肝细胞中的WT1表达用作肝，内皮和造血祖细胞的常见分子标记。 基于本发明，可以使用WT1基因表达水平作为指标来分离或检测肝，内皮和造血祖细胞。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.018 秒)
